Sexual side-effects of antidepressant and antipsychotic drugs

Current Opinion in Psychiatry

Volumn 28, Issue 6, 2015, Pages 418-423

  Montejo, Angel L ^a,b   Montejo, Laura ^a   Navarro Cremades, Felipe ^c  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Antidepressant; Antipsychotic; Compliance; Quality of life; Sexual dysfunction

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; DOPAMINE RECEPTOR; PSYCHOTROPIC AGENT; SEROTONIN RECEPTOR;

DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LONG TERM CARE; PATHOPHYSIOLOGY; POST HOC ANALYSIS; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SATISFACTION; SELF CONCEPT; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUAL INTERCOURSE; SEXUALITY; CHEMICALLY INDUCED; DRUG EFFECTS; ERECTILE DYSFUNCTION; FEMALE; LIBIDO; MALE; MEDICATION COMPLIANCE; METABOLISM; ORGASM; PSYCHOSEXUAL DISORDER; PSYCHOTIC DISORDERS;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ERECTILE DYSFUNCTION; FEMALE; HUMANS; LIBIDO; MALE; MEDICATION ADHERENCE; ORGASM; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; QUALITY OF LIFE; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 84942519309     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0000000000000198     Document Type: Review

References (55)

1. Quinn C, Happell B. Talking about sexuality with consumers of mental health services. Perspect Psychiatr Care 2013; 49:13-20.
2. Clayton AH, Croft HA, Handiwala L. Antidepressants and sexual dysfunction: mechanisms and clinical implications. Postgrad Med 2014; 126:91-99.
3. Baldwin DS, Foong T. Antidepressant drugs and sexual dysfunction. Br J Psychiatry 2013; 202:396-397.
4. Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 2006; 67:33-37.
5. Bijlsma EY, Chan JS, Olivier B, et al. Sexual side effects of serotonergic antidepressants: mediated by inhibition of serotonin on central dopamine release? Pharmacol Biochem Behav 2014; 121:88-101.
6. Segraves RT, Balon R. Antidepressant-induced sexual dysfunction in men. Pharmacol Biochem Behav 2014; 121:132-137.
7. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999; 19:67-85.
8. Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual Dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish working group for the study of psychotropic-related sexual dysfunction. J Clin Psychiatry 2001; 62:10-21.
9. Clayton A, Kornstein S, Prakash A, et al. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med 2007; 4:917-929.
10. Kennedy SH, Fulton KA, Bagby RM, et al. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatry 2006; 51:234-242.
11. Veening JG, de Jong TR, Waldinger MD, et al. The role of oxytocin in male and female reproductive behavior. Eur J Pharmacol 2015; 753:209-228.
12. La Torre A, Giupponi G, Duffy D, Conca A. Sexual dysfunction related to psychotropic drugs: a critical review. Part I: antidepressants. Pharmacopsy-chiatry 2013; 46:191-199.
13. Waldinger MD. Psychiatric disorders and sexual dysfunction. Handb Clin Neurol 2015; 130:469-489.
14. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009; 29:259-266.
15. Montejo-González AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997; 23:176-194.
16. Montejo AL, Garćia M, Espada M, et al. [Psychometric characteristics of the psychotropic-related sexual dysfunction questionnaire. Spanish work group for the study of psychotropic-related sexual dysfunctions]. Actas Esp Psiquiatr 2000; 28:141-150.
17. Reichenpfader U, Gartlehner G, Morgan LC, et al. Sexual dysfunction associated with second-generation antidepressants in patients with major depres sive disorder: results from a systematic review with network meta-analysis. Drug Saf 2014; 37:19-31.
18. Khin NA, Kronstein PD, Yang P, et al. Regulatory and scientific issues in studies to evaluate sexual dysfunction in antidepressant drug trials. J Clin Psychiatry 2015; 76:1060-1063.
19. Abler B, Seeringer A, Hartmann A, et al. Neural correlates of antidepressant-related sexual dysfunction: a placebo-controlled fMRI study on healthy males under subchronic paroxetine and bupropion. Neuropsychopharmacology 2011; 36:1837-1847.
20. De Bodinat C, Guardiola-Lemaitre B, Mocaër E, et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010; 9:628-642.
21. Montejo AL, Prieto N, Terleira A, et al. Better sexual acceptability of agome-latine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers: an 8-week, placebo-controlled study using the PRSEXDQ-SAL-SEX scale. J Psychopharmacol 2010; 24:111-120.
22. Montejo AL, Deakin JFW, Gaillard Raphael, et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers: a 9-week, placebo-controlled study using the PRSexDQ scale. J Psychopharmacol 2015; doi:10.1177/0269881115599385. [Epub ahead of print]
23. Taylor D, Sparshatt A, Varma S, et al. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 2014; 348:g1888.
24. Clayton AH, Reddy S, Focht K, et al. An evaluation of sexual functioning in employed outpatients with major depressive disorder treated with desvenla-faxine 50 mg or placebo. J Sex Med 2013; 10:768-776.
25. Clayton AH, Tourian KA, Focht K, et al. Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial. J Clin Psychiatry 2015; 76:562-569.
26. Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortiox-etine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2014; 10:1297-1307.
27. Mahableshwarkar AR, Jacobsen PL, Serenko M, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. J Clin Psychiatry 2015; 76:583-591.
28. Alam MY, Jacobsen PL, Chen Y, et al. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol 2014; 29:36-44.
29. Garnock-Jones KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs 2014; 28:855-874.
30. Clayton AH, Gommoll C, Chen D, et al. Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial. Int Clin Psychopharmacol 2015; 30:216-223.
31. Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2012; 66:356-368.
32. Deardorff WJ, Grossberg GT. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxe-tine. Expert Opin Pharmacother 2014; 15:2525-2542.
33. Trenque T, Maura G, Herlem E, et al. Reports of sexual disorders related to serotonin reuptake inhibitors in the French pharmacovigilance database: an example of underreporting. Drug Saf 2013; 36:515-519.
34. Takahashi H, Ishigooka J. Improvement of selective serotonin reuptake inhibitor-induced sexual dysfunction without worsening of depressive symptom after switchingtomilnacipran. Clin Neuropharmacol 2009; 32:177-178.
35. Baldwin D, Moreno RA, Briley M. Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Hum Psychopharmacol 2008; 23:527-532.
36. Keks NA, Hope J, Culhane C. Management of antidepressant-induced sexual dysfunction. Australas Psychiatry 2014; 22:525-528.
37. Clayton AH, Baker RA, Sheehan JJ, et al. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/seroto-nin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunc-tive treatment in a 52-week, open-label study. BMC Res Notes 2014; 7:459.
38. Fooladi E, Bell RJ, Jane F, et al. Testosterone improves antidepressant-emergent loss of libido in women: findings from a randomized, double-blind, placebo-controlled trial. J Sex Med 2014; 11:831-839.
39. Khamba B, Aucoin M, Lytle M, et al. Efficacy of acupuncture treatment of sexual dysfunction secondary to antidepressants. J Altern Compl Med 2013; 19:862-869.
40. Kashani L, Raisi F, Saroukhani S, et al. Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. Hum Psychopharmacol 2013; 28:54-60.
41. Dording CM, Schettler PJ, Dalton ED, et al. A double-blind placebo-controlled trial of maca root as treatment for antidepressant-induced sexual dysfunction in women. Evid Based Compl Altern Med 2015; 2015:949036.
42. Baldwin DS, Palazzo MC, Masdrakis VG. Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antide-pressants. Depress Res Treat 2013; 2013:256841.
43. Druyts E, Eapen S, Wu P, Thorlund K. The risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophre nia and schizophrenia spectrum disorders: protocol for a systematic review and meta-analysis. Syst Rev 2014; 3:116.
44. de Boer MK, Castelein S, Wiersma D, et al. The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings. Schizophr Bull 2015; 41:674-686.
45. Besnard I, Auclair V, Callery G, et al. [Antipsychotic-drug-induced hyperpro-lactinemia: physiopathology, clinical features and guidance]. Encephale 2014; 40:86-94.
46. Montejo AL, Majadas S, Rico-Villademoros F, et al., Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsycho-tics. J Sex Med 2010; 7:3404-3413.
47. Montejo AL, Rico-Villademoros F. Psychometric properties of the Psycho-tropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders. J Sex Marital Ther 2008; 34:227-239.
48. De Hert M, Detraux J, Peuskens J. Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review. Expert Opin Drug Saf 2014; 13:605-624.
49. de Boer MK, Castelein S, Bous J, et al. The Antipsychotics and Sexual Functioning Questionnaire (ASFQ): preliminary evidence for reliability and validity. Schizophr Res 2013; 150:410-415.
50. Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharma-col Bull 1997; 33:731-745.
51. deBoer MK, Castelein S, Wiersma D, et al. A systematic review ofinstruments to measure sexual functioning in patients using antipsychotics. J Sex Res 2014; 51: 383-389.
52. Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol 2011; 26:130-140.
53. Montejo AL, Montero Fernandez C, Pol Rodriguez J, et al. EPA-1652 sexuality and emotional life in people with severe long-term mental disorders. Eur Psychiatry 2014; 29:1.
54. Meng M, Li W, Zhang S, et al. Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials. Shanghai Arch Psychiatry 2015; 27:4-17. Review. Erratum in: Shanghai Arch Psychiatry 2015 Apr 25;27(2):89.
55. Basson R, Rees P, Wang R, et al. Sexual function in chronic illness. J Sex Med 2010; 7 (1 Pt 2):374-388.